"description","label","instanceType","name","uuid:ID","rationale","id"
"The main design for the study","","StudyDesign","Study Design 1","73766fc0-d8d7-4ed5-b03d-94ce829ce7a3","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
